Indus Biotech partners on sports supplement

Delaware, USA-based Extreme Physical Performance (EP2), a sport supplement firm, has partnered with Indus Biotech, a drug discovery  company that manufactures a new generation of safe and effective  ingredients that have been proven to show advancements in human physical  performance. Together, they aim to bring innovative new products to the  US market for bodybuilders and serious gym goers.

Torabolic is Indus' first novel ingredient that EP2 will bring to market  branded as Anabeutrol. Torabolic was clinically tested by Colin Wilborn  at his Human Performance Lab at the University of Mary Hardin Baylor.  The results of the double-blind, placebo-controlled study, says EP2,  "were incredible." Previously-trained Torabolic test subjects  significantly increased muscle mass and strength, while also losing fat.  In fact, it was proven that the Torabolic  group increased bench-press  strength by 100% and decreased fat by a whopping 475% over the placebo  group.

EP2's exclusive partnership with Indus has paved the way for the  development of proprietary ingredients not found in any other supplement  in the world. Recently, EP2 debuted Anabeutrol, its clinically-tested  supplement that stimulates muscle growth, metabolism of fat and cell  differentiation at an unprecedented rate. This year also saw the launch  of the long-awaited Andritest, claimed to be the bodybuilding's fastest  bioactive testosterone amplifier.